# US 2001/0024652 A1 · Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and used thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024652 A1
- Document ID: US20010024652A1
- Status: Published application
- Kind: A1
- Application number: 09/751,797
- Filed: 2000-12-29
- Published: 2001-09-27
- Earliest claimed: 1998-10-26
- Assignees: Ludwig Institute for Cancer Research
- Inventors: Laure Dumoutier; Jamila Louahed; Jean-Christophe Renauld
- Web page: https://patentgrep.com/patent/US20010024652A1

## CPC

- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell inducible factors.

## Claims

### Claim 1

An isolated nucleic acid molecule which encodes a T cell derived inducible factor, the complementary sequence of which hybridizes, under stringent conditions, to at least one of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:29, SEQ ID NO: 24 or SEQ ID NO:25.

### Claim 2 (depends on 1)

The isolated nucleic acid molecule of claim 1, wherein said isolated nucleic acid molecule encodes a protein having the amino acid sequence of the protein encoded by SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:29, SEQ ID NO: 24 or SEQ ID NO: 25.

### Claim 3 (depends on 1)

The isolated nucleic acid molecule of claim 1, wherein said molecule is cDNA.

### Claim 4 (depends on 1)

The isolated nucleic acid molecule of claim 1, wherein said molecule is genomic DNA.

### Claim 5 (depends on 2)

The isolated nucleic acid molecule of claim 2, the nucleotide sequence of which consists of the nucleotide sequence SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 29, SEQ ID NO: 24 or SEQ ID NO:25.

### Claim 6 (depends on 4)

The isolated nucleic acid molecule of claim 4, having the nucleotide sequence of SEQ ID NO: 25.

### Claim 7 (depends on 1)

An isolated nucleic acid molecule which encodes the protein encoded by the isolated nucleic acid molecule of claim 1.

### Claim 8 (depends on 1)

Expression vector comprising the isolated nucleic acid molecule of claim 1, operably linked to a promoter.

### Claim 9 (depends on 2)

Expression vector comprising the isolated nucleic acid molecule of claim 2, operably linked to a promoter.

### Claim 10 (depends on 3)

Expression vector comprising the isolated nucleic acid molecule of claim 3, operably linked to a promoter.

### Claim 11 (depends on 4)

Expression vector comprising the isolated nucleic acid molecule of claim 4, operably linked to a promoter.

### Claim 12 (depends on 5)

Expression vector comprising the isolated nucleic acid molecule of claim 5, operably linked to a promoter.

### Claim 13 (depends on 6)

Expression vector comprising the isolated nucleic acid molecule of claim 6, operably linked to a promoter.

### Claim 14 (depends on 1)

Recombinant cell comprising the isolated nucleic acid molecule of claim 1.

### Claim 15 (depends on 2)

Recombinant cell comprising the isolated nucleic acid molecule of claim 2.

### Claim 16 (depends on 8)

Recombinant cell comprising the expression vector of claim 8.

### Claim 17 (depends on 9)

Recombinant cell comprising the expression vector of claim 9.

### Claim 18 (depends on 10)

Recombinant cell comprising the expression vector of claim 10.

### Claim 19 (depends on 11)

Recombinant cell comprising the expression vector of claim 11.

### Claim 20 (depends on 1)

Isolated protein encoded by the isolated nucleic acid molecule of claim 1, and having a molecular weight of about 17-30 kilodaltons as determined by SDS-PAGE.

### Claim 21 (depends on 20)

The isolated protein of claim 20, comprising at least 120 amino acids of the protein encoded by SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:29, SEQ ID NO: 24, or SEQ ID NO: 25.

### Claim 22 (depends on 21)

The isolated protein of claim 21, comprising at least all but the 40 N terminal amino acids encoded by SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:29, SEQ ID NO: 24, or SEQ ID NO: 25.

### Claim 23 (depends on 22)

The isolated protein of claim 22, comprising at least all but the 20 N terminal amino acids encoded by SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:29, SEQ ID NO: 24, or SEQ ID NO: 25.

### Claim 24 (depends on 20)

Antibody which specifically binds to the isolated protein of claim 20.

### Claim 25 (depends on 24)

The antibody of claim 24, wherein said antibody is a monoclonal antibody.

### Claim 26

A method for determining effectiveness of interleukin-9 on a cell, comprising contacting said cell with an agent specific for at least one of (i) an isolated nucleic acid molecule which encodes a protein whose amino acid sequence is identical to the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:29, SEQ ID NO: 24 or SEQ ID NO: 25 and (ii) a protein whose amino acid sequence is identical to the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:29,SEQ ID NO: 24 or SEQ ID NO:25 and determining interaction of said agent with (i) or (ii) as a determination of effectiveness of interleukin-9 on said cell.

### Claim 27 (depends on 26)

The method of claim 26, wherein said agent is an antibody which specifically binds to (ii).

### Claim 28 (depends on 26)

The method of claim 26, wherein said agent comprises the isolated nucleic acid molecule of SEQ ID NO: 7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 29, SEQ ID NO:24, or SEQ ID NO: 25.

### Claim 29 (depends on 20)

A method for stimulating activation of a STAT protein comprising administering an amount of the protein of claim 20 sufficient to stimulate activation of said STAT protein.

### Claim 30 (depends on 29)

The method of claim 29, wherein said STAT protein is STAT1 , STAT3 or STAT5.

### Claim 31 (depends on 20)

A method of inhibiting activation of a STAT protein, comprising administering an amount of an antagonist of the protein of claim 20 sufficient to inhibit stimulation of expression of said STAT protein by said protein.

### Claim 32 (depends on 31)

The method of claim 31, wherein said STAT protein is STAT1, STAT3 or STAT5.

### Claim 33

A method for determining presence of TIF in a sample, comprising contacting said sample with an agent which binds to TIF or a nucleic acid molecule encoding TIF, and determining said binding as a determination of TIF in said sample.

### Claim 34 (depends on 33)

The method of claim 33, wherein said agent is an antibody.

### Claim 35 (depends on 33)

The method of claim 33, wherein said agent is a nucleic acid molecule.

### Claim 36

A method for screening to determine if a substance influences IL-9 activity, comprising adding said substance to a sample of TIF producing cells, in the presence of IL-9, and determining production of TIF, wherein a difference in production of TIF by said cells as compared to production of TIF by said cells in presence of IL-9 but not said substance indicates said substance influences IL-9 activity.

### Claim 37 (depends on 36)

The method of claim 36, wherein said substance is an IL-9 inhibitor or antagonist, said method further comprising determining lower levels of TIF production by said cells in the presence of said substance as compared to its absence.

### Claim 38 (depends on 36)

The method of claim 36, wherein said substance is an IL-9 activator, said method further comprising determining higher levels of TIF production by said cells in the presence of said substance as compared to its absence.

### Claim 39

A method for determining an aberrant level of IL-9 activity in a subject, comprising determining level of TIF in a subject and comparing said level to a normal level, differences therebetween being indicative of an aberrant level of IL-9 in said subject.

### Claim 40 (depends on 39)

The method of claim 39, wherein said aberrant level is excess endogenous IL-9.

### Claim 41 (depends on 39)

The method of claim 39, wherein said aberrant level is insufficient endogenous IL-9.

### Claim 42 (depends on 40)

The method of claim 40, wherein said subject suffers from asthma, an allergy, or lymphoma.

### Claim 43

A method for inhibiting IL-9 induced activity in a subject in need thereof, comprising administering an amount of a TIF inhibitor sufficient to inhibit IL-9 induced activity.

### Claim 44 (depends on 43)

The method of claim 43, wherein said TIF inhibitor is an antisense molecule.

### Claim 45 (depends on 43)

The method of claim 43, wherein said inhibitor is an antibody.

### Claim 46

A method for treating a subject suffering from asthma or an allergy, comprising administering to said subject an amount of a TIF mutein sufficient to alleviate said asthma or allergy.

### Claim 47

A method for determining if a mutein of TIF is therapeutically useful, comprising contacting a cell which produces IL-9 with said mutein, and determining effect of said mutein on prouction of IL-9, reduction thereof being indicative of possible thereapeutic efficacy for said mutein.

### Claim 48

A method for determining susceptibility to a condition characterized by aberrant expression of TIF, comprising determining nucleotide sequence of a TIF gene of a subject believed to possess an aberrant TIF gene, presence of an aberrant TIF gene being indicative of possible susceptibility to asthma or allergy.

### Claim 49 (depends on 48)

The method of claim 48, comprising contacting a sample taken from said subject with a pair of oligonucleotide primers which amplify said TIF gene.
